SynthesisSchizophrenia bulletin2026
Systematic Review and Meta-Analysis of Randomized Clinical Trials of Anti-Inflammatory Agents in Early-Stage Psychotic Disorders.
Synthesis in Schizophrenia bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Emerging Neurobiological and Therapeutic Insights into Schizophrenia: A Comprehensive Review.International journal of molecular sciences · 2026Review
- The kynurenine pathway in depression and schizophrenia: convergent signals, divergent states, and clinical signatures.EXCLI journal · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
background and hypothesisAccumulating evidence suggests that immune dysregulation is present in psychosis, however, evidence for anti-inflammatory treatments is mixed. This may be because studies need to focus on when inflammation offers a modifiable target. This review and meta-analysis sought to clarify the effects of anti-inflammatory agents from high-quality randomized trials in patients at clinical high risk for psychosis (CHR) and first-episode of psychosis (FEP). STUDY
designDatabases were searched until January 2025 for double-blind, randomized, placebo-controlled trials evaluating the effect of anti-inflammatory treatment compared with placebo in CHR and FEP populations. Primary outcomes were transition rates to psychosis in CHR and changes in total psychotic symptoms in FEP. Secondary outcomes included changes in symptoms in CHR and changes in symptom sub-scores in FEP. STUDY
resultsSearches retrieved 2168 articles, with 17 meeting inclusion criteria (5 for CHR, 12 for FEP). In CHR, anti-inflammatory treatment was not associated with a significant reduction in transition to psychosis (odds ratio 0.88, 95% CI, 0.26-3.01, P = .80). In FEP, anti-inflammatory treatment demonstrated a significant reduction in total psychotic symptoms; (standardized mean differences = -0.38, 95% CI, -0.76 to 0.00, P = .05). Secondary outcomes showed no change in symptoms in CHR, and significant changes in Positive and Negative Syndrome Scale positive sub-scores in FEP.
conclusionsAdjuvant anti-inflammatory treatment may be efficacious in FEP. However, high heterogeneity was present across studies, with possible publication bias and small-study effects. We highlight the need for further, large, stage-specific trials to conclusively understand the potential therapeutic benefit of anti-inflammatory treatments in early psychosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.